The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab ...

GSK plc has received approval for Blenrep combinations from Japan's Ministry of Health, Labour and Welfare (MHLW) for the ...

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved UK pharma major GSK’s (LSE: GSK) Blenrep (belantamab ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

GSK’s Blenrep combinations receives Japanese approval for treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, May 20, 2025, 12:00 Hrs [IST] GSK plc announced ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple myeloma (MM).

Laying this groundwork will help firmly establish Blenrep in the second-line multiple myeloma market and demonstrate the benefits of this transformative medicine. Turning to respiratory.

GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or ...

GSK's Blenrep treatment has been approved by Japanese regulators when in combination for relapsed or refractory multiple myeloma, marking the second major approval of its kind for the drug, with more ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple myeloma (MM). This authorisation is said to be a global first for Blenrep ...